Investigation of soluble HER2 and transforming growth factor Beta-1 serum levels in gestational trophoblastic disease.
HER2/neu and TGF-beta1 are over-expressed in various types of malignancies. It appears that they play an important role in the biologic behavior of tumors and have prognostic value. Gestational tropoblastic diseases (GTDs) comprise of a heterogeneous group characterized by abnormally proliferating trophoblastic tissues, ranging from benign to malignant. The objective of this study was to measure and compare the serum levels of s-HER2 and TGF-beta between patients with GTDs and pregnant and non-pregnant controls. Serum levels of s-HER2 and TGF-beta1 were determined by ELISA method in 95 GTD patients (55 complete moles, 32 persistent moles, and 8 choriocarcinoma), 30 normal pregnant controls, and 22 normal non-pregnant controls. Mean serum level of s-HER2 did not differ significantly between patients and controls. TGF-beta1 serum level was significantly higher in GTD patients (20.29 +/- 10.68 pg/ml with 95% confidence interval (CI) of 18.10-22.48 pg/ml) compared with pregnant controls (10.26 +/- 11.84 pg/ml with 95% CI of 5.75-14.76 pg/ml) and non-pregnant controls (7.27 +/- 9.61 pg/ml with 95% CI of 3.01-11.53 pg/ml) (P < 0.001). Our findings suggest that TGF-beta1 serum levels in GTD patients may represent a potential prognostic marker. Further investigations with larger sample size and more frequent sampling are required to elucidate this issue.
Dehaghani
Alamtaj Samsami
AS
Department of Obstetric and Gynecology, Hafez hospital, Shiraz University of Medical Sciences, 71345-1798, Shiraz, Iran. samsamia@sums.ac.ir
Rad
Neda Rahimi
NR
Fattahi
Mohammad Javad
MJ
Khadang
Baharak
B
Kashef
Mohammad Amin
MA
Sarraf
Zahra
Z
Ghaderi
Abbas
A
D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000097:blood* / Q000473:pathology; D006801:Humans; D011247:Pregnancy; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D053773:Transforming Growth Factor beta1 / Q000097:blood*
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D053773:Transforming Growth Factor beta1; C508053:ERBB2 protein, human